Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 237

Similar articles for PubMed (Select 18760140)

1.

Angiotensin inhibition in renovascular disease: a population-based cohort study.

Hackam DG, Duong-Hua ML, Mamdani M, Li P, Tobe SW, Spence JD, Garg AX.

Am Heart J. 2008 Sep;156(3):549-55. doi: 10.1016/j.ahj.2008.05.013. Epub 2008 Jul 21.

PMID:
18760140
2.

The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.

Sumner G, Salehian O, Yi Q, Healey J, Mathew J, Al-Merri K, Al-Nemer K, Mann JF, Dagenais G, Lonn E; HOPE Investigators.

J Cardiovasc Electrophysiol. 2009 Jul;20(7):781-7. doi: 10.1111/j.1540-8167.2009.01440.x. Epub 2009 Feb 27.

PMID:
19298567
3.
4.

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.

5.

Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.

Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, Valsecchi MG.

Am J Kidney Dis. 2008 Feb;51(2):255-62. doi: 10.1053/j.ajkd.2007.10.034.

PMID:
18215703
6.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.

Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.

Am Heart J. 2007 Jun;153(6):1064-73.

PMID:
17540211
7.

Statin use and survival outcomes in elderly patients with heart failure.

Ray JG, Gong Y, Sykora K, Tu JV.

Arch Intern Med. 2005 Jan 10;165(1):62-7.

PMID:
15642876
8.

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S.

Ann Intern Med. 2001 Apr 17;134(8):629-36.

PMID:
11304102
9.
10.
11.

Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study.

van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH.

Cancer. 2008 Feb 15;112(4):748-57. doi: 10.1002/cncr.23215.

12.

Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study.

Ishani A, Collins AJ, Herzog CA, Foley RN.

Kidney Int. 2005 Jul;68(1):311-8.

PMID:
15954922
13.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

14.

The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.

Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML.

Eur Heart J. 2009 Jun;30(11):1385-94. doi: 10.1093/eurheartj/ehp103. Epub 2009 Apr 4.

15.

Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.

Levin A, Djurdjev O, Beaulieu M, Er L.

Am J Kidney Dis. 2008 Oct;52(4):661-71. doi: 10.1053/j.ajkd.2008.06.023.

PMID:
18805347
16.

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.

Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E.

Am Heart J. 2008 May;155(5):791-805. doi: 10.1016/j.ahj.2008.01.031. Erratum in: Am Heart J. 2009 Mar;157(3):501. Jalandara, Nishant [corrected to Jalandhara, Nishant].

PMID:
18440325
17.

Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect?

Ishani A, Herzog CA, Collins AJ, Foley RN.

Kidney Int. 2004 Mar;65(3):1017-25.

PMID:
14871422
18.

Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.

Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM.

J Am Coll Cardiol. 2006 Jun 20;47(12):2554-60. Epub 2006 May 2.

19.

Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.

Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD.

Hypertension. 2008 Jan;51(1):48-54. Epub 2007 Nov 19.

20.

Blocking the renin-angiotensin system: dual- versus mono-therapy.

Ravandi A, Teo KK.

Expert Rev Cardiovasc Ther. 2009 Jun;7(6):667-74. doi: 10.1586/erc.09.47. Review.

PMID:
19505282
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk